Showing posts with label EORTC. Show all posts
Showing posts with label EORTC. Show all posts
Friday, February 17, 2012
Still waiting for the world to catch up - Ignace Vergote - Cancer World - including comments on CA-125/biomarkers
" He believes that more accurate tumour markers than CA125 need to be found – and his department is working on this problem.
add your opinions
EORTC
,
Europe
,
Ignace Vergote
Saturday, January 29, 2011
Lancet (abstract) Retraction: validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
Note: full details available to subscribers ($$$)
Comment
Retraction—validation of gene signatures that predict the response of
breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC
10994/BIG 00-01 clinical trial
add your opinions
BIG 00-01 trial
,
breast
,
EORTC
,
gene signatures
Saturday, January 22, 2011
short (very) commentary: EORTC 55971: Does it apply to all patients with advanced state ovarian cancer?
Research Highlights
► Within this randomized trial a statistical benefit was seen with primary
surgery among patients with less than 5 cm of upper abdominal
disease (HR 0.64).
► Across different countries in this study there was significant
heterogeneity of the benefit of primary cytoreductive surgery.
refers to:
EORTC Newsletter Results of the EORTC 55971 trial: Neoadjuvant
chemotherapy followed by interval debulking surgery is not inferior to
primary debulking surgery followed by chemotherapy as a treatment
option for patients with stage IIIC or IV ovarian carcinoma
add your opinions
EORTC
,
primary surgery
Friday, December 17, 2010
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
add your opinions
blood products
,
EORTC
,
Europe
,
febrile neutropenia
,
granulocyte colone stimulating
,
guidelines
Sunday, August 08, 2010
abstract: How to follow-up patients with epithelial ovarian cancer : Current Opinion in Oncology
How to follow-up patients with epithelial ovarian cancer
Miller, Rowan E; Rustin, Gordon JS
Abstract
Purpose of review: Despite optimal primary treatment most patients with advanced epithelial ovarian cancer will relapse. This review discusses the controversy regarding surveillance and the timing of treatment for recurrent disease.
Recent findings: Routine physical examination has a limited role in the detection of recurrent ovarian cancer. PET/computed tomography (CT) has been shown to be useful in detecting small volume disease not apparent on traditional imaging in patients with suspected recurrence based on symptoms and/or rising CA125. The results of PET/CT can alter treatment plans and have particular use in guiding site-directed therapy. The benefits of early detection and systemic treatment of recurrence are now in doubt following the presentation of the MRC/EORTC CA125 surveillance trial. The impact on survival of secondary cytoreductive surgery requires more investigation.
Summary: Uncertainties remain in the surveillance and timing of treatment for relapsed disease. Patients should be informed of these uncertainties and become involved in decisions regarding their follow-up.
add your opinions
10 year followup
,
breast conserving surgery
,
clincial trials
,
CT
,
early detection
,
EORTC
,
epithelial ovarian cancer
,
follow-up
,
MRC
,
patient involvement
,
PET
,
physical examinations
,
surveillance
Wednesday, May 26, 2010
abstract: How to follow-up patients with epithelial ovarian cancer.
Abstract
PURPOSE OF REVIEW: Despite optimal primary treatment most patients with advanced epithelial ovarian cancer will relapse. This review discusses the controversy regarding surveillance and the timing of treatment for recurrent disease.
RECENT FINDINGS: Routine physical examination has a limited role in the detection of recurrent ovarian cancer. PET/computed tomography (CT) has been shown to be useful in detecting small volume disease not apparent on traditional imaging in patients with suspected recurrence based on symptoms and/or rising CA125. The results of PET/CT can alter treatment plans and have particular use in guiding site-directed therapy. The benefits of early detection and systemic treatment of recurrence are now in doubt following the presentation of the MRC/EORTC CA125 surveillance trial. The impact on survival of secondary cytoreductive surgery requires more investigation.
SUMMARY: Uncertainties remain in the surveillance and timing of treatment for relapsed disease. Patients should be informed of these uncertainties and become involved in decisions regarding their follow-up.
Subscribe to:
Posts
(
Atom
)